Deintensification of Diabetes Medication Based on A1C Levels

Primary Recommendations for Medication Reduction

The American College of Physicians recommends deintensifying pharmacologic therapy in patients with type 2 diabetes who achieve HbA1c levels less than 6.5%, as no trials show that targeting levels below this threshold improves clinical outcomes, while pharmacologic treatment below this target has substantial harms 1
When deintensifying therapy, consider reducing the dosage, removing a medication if the patient is receiving more than one, or discontinuing pharmacologic treatment altogether, as recommended by the American College of Physicians 1
For patients with A1C less than 6.5%, the risk of hypoglycemia and other adverse effects outweighs potential benefits, particularly with insulin and sulfonylureas, according to the American College of Physicians 2

A reasonable A1C goal is less than 7% for many non-pregnant adults without significant hypoglycemia risk, as suggested by the American Diabetes Association 3
Consider deintensification when A1C is below target, especially if below 6.5%, as recommended by the American College of Physicians 1, 2

When deintensifying therapy for patients with A1C below 6.5%, consider the medication class, prioritizing reduction of insulin and sulfonylureas due to high hypoglycemia risk, as recommended by the American College of Physicians 1, 4
Metformin has a low risk of hypoglycemia but still has other known adverse effects, according to the American College of Physicians 1
Consider switching to medication classes with lower hypoglycemia risk for high-risk individuals, as suggested by the American Diabetes Association 5

Achieving lower A1C levels often requires more intensive regimens that increase the risk of adverse effects, including hypoglycemia, weight gain, and medication burden, as noted by the American College of Physicians 2
Metformin, despite having a low hypoglycemia risk, may still contribute to polypharmacy burden with little benefit when A1C is already below target, according to the American College of Physicians 1

Measure current A1C level, and if A1C is <6.5%, evaluate current medication regimen, assess hypoglycemia risk, and consider patient's age, comorbidities, and life expectancy, as recommended by the American Diabetes Association 3 and the American College of Physicians 1
Implement deintensification strategy, focusing on symptom management rather than A1C targets for elderly patients or those with limited life expectancy, as recommended by the American College of Physicians 1, 4